---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-014204"
form_type: "8-K"
ticker: "CVM"
cik: "0000725363"
company_name: "CEL SCI CORP"
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T01:23:52.641504+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# CEL-SCI appoints Dr. Nabil Saba as lead for Phase III Multikine study in head and neck cancer

## Summary
- Dr. Saba will serve as global Phase III confirmatory trial lead and Study Steering Committee member for Multikine.
- He is a recognized head and neck cancer expert, professor at Emory, and has led over 50 clinical trials.
- Appointment positions CEL-SCI for its upcoming confirmatory registration study in newly diagnosed head and neck cancer.
- Dr. Saba chairs NCI head and neck cancer task forces and holds NIH funding for related research.

## SEC filing metadata
- accession: 0001654954-24-014204
- form_type: 8-K
- ticker: CVM
- cik: 0000725363
- company_name: CEL SCI CORP
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/725363/000165495424014204/0001654954-24-014204-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/725363/000165495424014204/cvm_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-014204
- JSON: https://secwatch.observer/filing/0001654954-24-014204.json
- Plain text: https://secwatch.observer/filing/0001654954-24-014204.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.